

**PATENT APPLICATION****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q95342

Woo Heon SONG, et al.

Appln. No.: 10/596,187

Group Art Unit: Unknown

Confirmation No.: 3273

Examiner: Unknown

Filed: June 2, 2006

For: THE ENTERIC COATED PHARMACEUTICAL ORAL FORMULATIONS
COMPRISING ACID-LABILE ACTIVE SUBSTANCES, AND A METHOD THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. U.S. Patent No. 6,013,281 A issued January 11, 2000.
2. WO 92/22284, published December 23, 1992 with English Abstract.
3. EP Patent Application No. 0 247 983 A2, published December 2, 1987.
4. U.S. Patent No. 4,853,230 issued August 1, 1989.
5. JP Patent Application No. 1-290628 A, published November 22, 1989 with English Abstract.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./

Woo Heon SONG, et al.
U.S. Appln. No.: 10/596,187
INFORMATION DISCLOSURE STATEMENT

6. Abstract of U.S. Patent No. 6,602,522 issued August 5, 2003.

One copy of each of the listed documents is submitted herewith, except for the following:

U.S. patents.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under § 1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Sunhee Lee
Registration No. 53,892

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373


CUSTOMER NUMBER

Date: August 30, 2006

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Complete if Known

Application Number	10/596,187
Confirmation Number	3273
Filing Date	June 2, 2006
First Named Inventor	Woo Heon SONG
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q95342

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
	/D.B./	US 6,013,281	A	01/11/2000	Lundberg et al.
	/D.B./	US 4,853,230		08/01/1989	Lovgren
	/D.B./	US 6,602,522		08/05/2003	Andrx Pharmaceuticals
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
	/D.B./	WO	92/22284	A1	12/23/1992		English Abstract
	/D.B./	EP	0 247 983	A2	12/02/1987		
	/D.B./	JP	1-290628	A	11/22/1989		English Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶

Examiner Signature

/David Browe/

Date Considered

08/27/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./